Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 21:14:1342671.
doi: 10.3389/fonc.2024.1342671. eCollection 2024.

Clinical analysis of 82 cases of acute promyelocytic leukemia with PML-RARα short isoform in children and adults

Affiliations

Clinical analysis of 82 cases of acute promyelocytic leukemia with PML-RARα short isoform in children and adults

Qiaolin Huang et al. Front Oncol. .

Abstract

Background: Acute promyelocytic leukemia (APL) with PML/RARα fusion gene is a distinct variant of acute myeloid leukemia. According to the different break sites of the PML gene, there are three transcripts: Long (bcr1), Variant (bcr2) and Short (bcr3).

Methods: We retrospectively analyzed 82 APL cases with PML-RARα short isoform.

Results: A total of 384 patients with APL were seen, of which 85(22.14%) had PML/RARα short isoform (bcr3) and 82 met the inclusion criteria. The median age was 33.5 years (range, 2-72 years). The incidences of hemorrhage in the intermediate- and high-risk group were higher, but only the incidence between medium and low risk differed statistically (P=0.006), and the incidences of fever, fatigue, splenomegaly, and lymph node enlargement and differentiation syndrome (DS) in those groups were not statistically significant (P>0.05). FLT3 gene mutation rate and the mortality rate of the high-risk group were significantly higher than that of other groups (P=0.040 and P=0.004, P=0.041 and P=0.037, respectively). The mortality rate was lowest (4.26%) in the group treated with ATRA combined with arsenic and anthracycline. The 3-year OS and the 3-year DFS of the low and intermediate-risk group were better (P=0.019 and P=0.017, respectively).

Conclusions: ATRA combined with arsenic and anthracycline had significant impact on outcomes in APL with PML-RARα short isoform.

Keywords: PML-RARα short isoform; acute promyelocytic leukemia; bcr3 isoform; clinical features; gene mutation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Kaplan-Meier estimates of overall survival based on risk groups. Kaplan-Meier curves showing 3 years landmark analysis for OS (Overall Survival) of patients with PML/RARα S fusion gene since the diagnosis of this disease. The low and intermediate risk group compared with the high risk group, and the difference was significant (P=0.019). Groups were compared by log-rank test.
Figure 2
Figure 2
Kaplan-Meier estimates of disease-free survival based on risk groups. Note: Kaplan-Meier curves showing 3 years landmark analysis for DFS (disease-free survival) of patients with PML/RARα S fusion gene achieving the first remission. The low and intermediate risk group compared with the high risk group, and the difference was significant (P=0.017). Groups were compared by log-rank test.

Similar articles

References

    1. Jiang Y, Ji M, Deng W, Gu J, Guan J, He B, et al. . Clinical study of PML-RARα fusion gene in acute promyelocytic leukemia. J Pract Clin Med. (2003) 04):331–4. doi: 10.3969/j.issn.1672-2353.2003.04.014 - DOI
    1. Alcalay M, Zangrilli D, Fagioli M, Pandolfi PP, Mencarelli A, Lo Coco F, et al. . Expression pattern of the RAR alpha-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci USA. (1992) 89:4840–4. doi: 10.1073/pnas.89.11.4840 - DOI - PMC - PubMed
    1. Guan W, Zhou L, Li Y, Yang E, Liu Y, Lv N, et al. . Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns. Exp Hematol Oncol. (2021) 10:27. doi: 10.1186/s40164-021-00207-4 - DOI - PMC - PubMed
    1. Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. (2021) 11:123. doi: 10.1038/s41408-021-00514-3 - DOI - PMC - PubMed
    1. Chen WW, Pan Y, Sun FJ, Xia T, Cheng XS. Clinical characteristics and prognosis of patients with PML/RARα subtype and acute promyelocytic leukemia. Systemic Med. (2022) 7:27–31.